Gene Solutions and Pangea Lab伙伴验证美国人工智能液体活性细胞 在美国早期检测癌症 Gene Solutions and Pangea Lab partner to validate AI-powered liquid biopsies for early cancer detection in the U.S.

Gene Solutions和Pangea实验室建立了伙伴关系,在美国验证用于癌症检测和监测的液体生物检查,将Gene Solutions的AI驱动的多组化平台-SPOT-MAS和K-4CARE-与Pangea的CLIA/CAP认证鉴定专家相结合。 Gene Solutions and Pangea Laboratory have formed a partnership to validate liquid biopsy tests for cancer detection and monitoring in the U.S., combining Gene Solutions’ AI-driven multi-omics platforms—SPOT-MAS and K-4CARE—with Pangea’s CLIA/CAP-accredited validation expertise. 合作的目的是根据美国监管标准加快提供这些测试,利用血液样本的CtDNA分析检测早期癌症信号和指导治疗。 The collaboration aims to accelerate the availability of these tests under U.S. regulatory standards, using ctDNA analysis from blood samples to detect early cancer signals and guide treatment. 两家公司都强调测试仅用于专业用途,补充标准筛选,可用性因地区而异。 Both companies stress the tests are for professional use only, complement standard screening, and availability varies by region.